The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.
作者信息
Cox G, Steward W P, O'Byrne K J
机构信息
University Department of Medical Oncology, Leicester Royal Infirmary, UK.
出版信息
Thorax. 1999 Feb;54(2):169-79. doi: 10.1136/thx.54.2.169.
Abstract
摘要
相似文献
1
The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.非小细胞肺癌中的纤溶酶级联反应与基质金属蛋白酶
Thorax. 1999 Feb;54(2):169-79. doi: 10.1136/thx.54.2.169.
2
New perspectives in lung cancer. 2. Growth factors and lung cancer.肺癌的新视角。2. 生长因子与肺癌
Thorax. 1991 Dec;46(12):924-9. doi: 10.1136/thx.46.12.924.
3
Growth factors, antagonists and lung cancer.生长因子、拮抗剂与肺癌
J R Soc Med. 1993 Nov;86(11):621-2.
4
The new drugs and biologics as sensitizers in the treatment of non-small cell lung cancer.用于治疗非小细胞肺癌的新型致敏药物和生物制剂。
Suppl Tumori. 2002 Jul-Aug;1(4):S55-7.
5
Targeting the epidermal growth factor receptor a new strategy in cancer treatment.靶向表皮生长因子受体：癌症治疗的新策略
Suppl Tumori. 2002 Jul-Aug;1(4):S60-1.
6
A therapeutic target for smoking-associated lung cancer.吸烟相关肺癌的治疗靶点。
Sci Transl Med. 2010 Dec 15;2(62):62ps56. doi: 10.1126/scitranslmed.3001942.
7
Chemotherapy for advanced non-small-cell lung cancer.晚期非小细胞肺癌的化疗
Clin Adv Hematol Oncol. 2004 Mar;2(3):173-8.
8
Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt?
J Natl Cancer Inst. 2004 Aug 4;96(15):1117-9. doi: 10.1093/jnci/djh244.
9
Matrix metalloproteinase expression in lung cancer.
Methods Mol Med. 2003;74:349-56. doi: 10.1385/1-59259-323-2:349.
10
Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.基质金属蛋白酶抑制剂马立马司他联合卡铂和紫杉醇用于晚期非小细胞肺癌患者的I期试验。
Clin Cancer Res. 2005 May 1;11(9):3417-24. doi: 10.1158/1078-0432.CCR-04-2144.
引用本文的文献
1
Cancer and apoptosis: The apoptotic activity of plant and marine natural products and their potential as targeted cancer therapeutics.癌症与细胞凋亡：植物和海洋天然产物的凋亡活性及其作为靶向癌症治疗药物的潜力。
Front Pharmacol. 2022 Aug 10;13:842376. doi: 10.3389/fphar.2022.842376. eCollection 2022.
2
Breast Cancer: A Global Concern, Diagnostic and Therapeutic Perspectives, Mechanistic Targets in Drug Development.乳腺癌：全球关注的问题、诊断与治疗前景、药物研发中的作用机制靶点
Adv Pharm Bull. 2021 Sep;11(4):580-594. doi: 10.34172/apb.2021.068. Epub 2020 Oct 14.
3
Role of epidermal growth factor receptor in lung cancer and targeted therapies.表皮生长因子受体在肺癌中的作用及靶向治疗
Am J Cancer Res. 2017 Feb 1;7(2):187-202. eCollection 2017.
4
Plasminogen Activator Inhibitor-2 Plays a Leading Prognostic Role among Protease Families in Non-Small Cell Lung Cancer.纤溶酶原激活物抑制剂-2在非小细胞肺癌蛋白酶家族中起主要预后作用。
PLoS One. 2015 Jul 31;10(7):e0133411. doi: 10.1371/journal.pone.0133411. eCollection 2015.
5
Prognostic effect of matrix metalloproteinase-9 in patients with resected Non small cell lung cancer.基质金属蛋白酶-9对非小细胞肺癌切除患者的预后影响
J Cardiothorac Surg. 2015 Mar 27;10:44. doi: 10.1186/s13019-015-0248-3.
6
Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression.过敏毒素 C5a 为肺癌的进展创造了有利的微环境。
J Immunol. 2012 Nov 1;189(9):4674-83. doi: 10.4049/jimmunol.1201654. Epub 2012 Oct 1.
7
PEGylated DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor.聚乙二醇化DX-1000：一种特异性纤溶酶抑制剂的药代动力学和抗肿瘤活性
Neoplasia. 2007 Nov;9(11):927-37. doi: 10.1593/neo.07544.
8
Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer.组织因子途径抑制物-2基因在非小细胞肺癌中的表达及甲基化状态
Br J Cancer. 2005 Feb 28;92(4):775-83. doi: 10.1038/sj.bjc.6602298.
9
A hybrid protein of the amino-terminal fragment of urokinase and mutant plasminogen activator inhibitor-2 efficiently inhibits tumor cell invasion and metastasis.尿激酶氨基末端片段与突变型纤溶酶原激活物抑制剂-2的杂合蛋白可有效抑制肿瘤细胞的侵袭和转移。
J Cancer Res Clin Oncol. 2005 Feb;131(2):129-36. doi: 10.1007/s00432-004-0623-2. Epub 2004 Oct 12.
10
Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura.基质金属蛋白酶2和9（明胶酶A和B）在恶性间皮瘤和良性胸膜中的表达
Br J Cancer. 2003 May 19;88(10):1553-9. doi: 10.1038/sj.bjc.6600920.
本文引用的文献
1
TIMP1 and adverse prognosis in non-small cell lung cancer.基质金属蛋白酶组织抑制因子1与非小细胞肺癌的不良预后
Clin Cancer Res. 1996 Aug;2(8):1369-72.
2
3
4
Selective inhibition by kringle 5 of human plasminogen on endothelial cell migration, an important process in angiogenesis.kringle 5对人纤溶酶原在内皮细胞迁移（血管生成中的一个重要过程）方面的选择性抑制作用。
Biochem Biophys Res Commun. 1998 Jun 18;247(2):414-9. doi: 10.1006/bbrc.1998.8825.
5
6
Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis.金属蛋白酶组织抑制剂-1、-2或-3过表达对大鼠血管平滑肌细胞体外侵袭、增殖及死亡的不同影响。金属蛋白酶组织抑制剂-3促进细胞凋亡。
J Clin Invest. 1998 Mar 15;101(6):1478-87. doi: 10.1172/JCI1584.
7
Reduced angiogenesis and tumor progression in gelatinase A-deficient mice.明胶酶A缺陷小鼠的血管生成减少与肿瘤进展减缓
Cancer Res. 1998 Mar 1;58(5):1048-51.
8
Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro.血管内皮生长因子可增加体外微血管内皮细胞中明胶酶A的释放，并减少金属蛋白酶组织抑制剂的释放。
Microvasc Res. 1998 Jan;55(1):29-42. doi: 10.1006/mvre.1997.2056.
9
TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis.组织金属蛋白酶抑制因子-2（TIMP-2）的过表达可减少侵袭和血管生成，并保护B16F10黑色素瘤细胞免于凋亡。
Int J Cancer. 1998 Jan 19;75(2):246-53. doi: 10.1002/(sici)1097-0215(19980119)75:2<246::aid-ijc13>3.0.co;2-b.
10
Potential role of bcl-2 as a suppressor of tumour angiogenesis in non-small-cell lung cancer.bcl-2作为非小细胞肺癌肿瘤血管生成抑制因子的潜在作用。
Int J Cancer. 1997 Dec 19;74(6):565-70. doi: 10.1002/(sici)1097-0215(19971219)74:6<565::aid-ijc1>3.0.co;2-s.
Zotero 插件